Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of RSV Vaccines in Children and Infants
NCT03596801Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jun 2018
- Primary completion
- Apr 2024
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised trial of RSV 6120/∆NS1 and RSV 6120/F1/G2/∆NS1 in respiratory syncytial virus infection (RSV) (6 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Number of Participants With Solicited Adverse Events by Grade at Day 28, Number of Participants With Unsolicited Adverse Events at Day 28 and 7 more. Started Jun 2018; status: completed.
02
Drugs
RSV 6120/∆NS1RSV 6120/F1/G2/∆NS1
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT03596801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03596801.